Skip to content
TrialScanner

NCT04797715

Assessing Clinical Outcomes in Alzheimer's Disease Agitation

Phase 3CompletedAXSMLead

Registry record

Lead sponsor
Axsome Therapeutics, Inc.
Conditions
Agitation in Patients With Dementia of the Alzheimer's Type; Alzheimer Disease; Agitation,Psychomotor
Primary completion
Nov 21, 2022Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT04797715 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT04797715: Assessing Clinical Outcomes... | TrialScanner